History 2025

L-methylfolate and MethylB12 have a long history of use in prescription medical foods. They have been very successful for use particularly in type 2 diabetes patients for peripheral neuropathy. Several clinical studies have supported their use, where they were shown to restore microvascular blood flow and nerve function.

Today

Clinical studies of dietary management with Ocufolin^® show improved metabolic markers of folate metabolism in patients with impaired folate metabolism. We believe these to be responsible for improvements in retinal blood flow and microvascular architecture.

The key ingredients of Ocufolin^® are L-methylfolate and methylcobalamin. These are the active forms of vitamins B9 (folate) and B12 (cobalamin) which are synthesized during folate metabolism. Inborn errors of folate metabolism, such as the reduced function variants MTHFR C677T and A1298C, decrease the availability of these essential vitamin forms. The downstream consequences include microvascular injury, impaired retinal perfusion, and ischemia.

The Bascom Palmer Eye Institute has conducted clinical trials to study the value of Ocufolin^® for managing the metabolic consequences of these common MTHFR variants for retinopathy patients with diabetes.

Healthcare providers may request a summary of peer reviewed papers that studied or recommend Ocufolin^®.